改良された分散性を有する乾燥粉末組成物

Japanese Patent JP4859320

B2

The present invention provides a highly dispersible formulation comprising an active agent and a tripeptide comprising at least two leucyl residues. The composition of the invention possesses superior aerosol properties and is thus preferred for aerosolized administration to the lung. Also provided is a method for increasing the aerosol performance of an active-agent containing formulation for administration to the lung, which comprises the incorporation of a di- or tripeptide comprising at least two leucines into a formulation comprising an active agent.

JP5260863	Pharmaceutical composition for psychiatric or cranial nerve disorders, comprising atelocollagen and stem cells
JP2014207907	NOVEL THERAPEUTIC RNA INTERFERENCE TECHNOLOGY TARGETED TO PDX-1 ONCOGENE IN PDX-1 EXPRESSING NEUROENDOCRINE TUMORS
JP2009529030	CC-1065 analog improved prodrug

Lechuga Ballesteros, David
Kuo, May-Chan

JP2001534349A

January 25, 2012

April 12, 2000

Click for automatic bibliography generation  

Nectar Therapeutics

A61K47/42; A61K9/00; A61K9/08; A61K9/12; A61K9/14; A61K9/72; A61K31/58; A61K38/00; A61K38/21; A61K38/22; A61K38/23; A61K38/27; A61K38/28; A61K38/43; A61K38/55; A61K39/395; A61K45/00; A61K47/12; A61K47/16; A61K47/18; A61K47/26; A61K47/30; A61P1/04; A61P1/08; A61P3/02; A61P3/04; A61P3/06; A61P3/10; A61P5/00; A61P5/28; A61P7/02; A61P7/12; A61P9/00; A61P9/06; A61P9/12; A61P11/00; A61P11/06; A61P11/08; A61P15/18; A61P19/02; A61P21/00; A61P25/02; A61P25/06; A61P25/08; A61P25/16; A61P25/18; A61P25/20; A61P25/22; A61P25/26; A61P29/00; A61P31/00; A61P31/04; A61P31/10; A61P31/12; A61P33/06; A61P33/10; A61P35/00; A61P37/00; A61P39/06

JPH09235238A

1997-09-09

Hidesaku Yamamoto
Takaaki Yasumura
Natsuki Morishita

Previous Patent: JPS4859319

Next Patent: 新規の［１，２，３］−トリアゾロ［４，５−Ｄ］ピリミジン化合物